Literature DB >> 7691952

Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2.

J P Deans1, G L Schieven, G L Shu, M A Valentine, L A Gilliland, A Aruffo, E A Clark, J A Ledbetter.   

Abstract

CD20 is a B cell-specific 35/37 kDa integral membrane protein which modulates proliferation and differentiation of normal resting B cells when stimulated by CD20 antibodies. An increase in c-myc mRNA levels occurs within hours after treatment of resting B cells with CD20 mAb; however earlier events in the CD20 signal transduction pathway have not been described. Here we demonstrate that anti-CD20 mediated induction of c-myc mRNA is inhibited by the tyrosine kinase inhibitor herbimycin A, that CD20 is associated with both tyrosine and serine kinase activity, and that tyrosine phosphorylation of multiple substrates is induced within minutes upon ligation of CD20 with mAb. Association of the tyrosine and serine kinases with CD20 was stable in lysis buffer containing 1% NP40 and 0.25% deoxycholate. Under the same conditions, antibodies against several other B cell surface molecules failed to co-precipitate tyrosine kinase activity, however, a serine kinase was precipitated by the anti-CD19 mAb, B43. Both phospholipase C-gamma 1 and -gamma 2 were phosphorylated on tyrosine after cross-linking of CD20-bound mAb, and this correlated with increases in intracellular calcium that were partially resistant to depletion of extracellular calcium with EGTA. The pattern of tyrosine phosphorylated proteins observed in whole cell lysates after anti-CD20 cross-linking appeared to be a subset of those induced by anti-IgM; however, differences in phosphoproteins induced by anti-IgM and anti-CD20 were detected using a fynSH2-fusion protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691952

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Calcium channels in lymphocytes.

Authors:  G Grafton; L Thwaite
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 3.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 4.  Lipid raft: A floating island of death or survival.

Authors:  Kimberly S George; Shiyong Wu
Journal:  Toxicol Appl Pharmacol       Date:  2012-01-24       Impact factor: 4.219

5.  Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

Authors:  E Janas; R Priest; J I Wilde; J H White; R Malhotra
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.

Authors:  Tammy L Unruh; Haidong Li; Cathlin M Mutch; Neda Shariat; Lana Grigoriou; Ratna Sanyal; Christopher B Brown; Julie P Deans
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 7.  How does B cell depletion therapy work, and how can it be improved?

Authors:  E A Clark; J A Ledbetter
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

8.  Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for MS4a4B, a CD20 homolog in Th1 T cells.

Authors:  Hui Xu; Mark S Williams; Lisa M Spain
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 9.  Rituximab in immunologic glomerular diseases.

Authors:  A Ahsan Ejaz; Abdo Asmar; Mourad M Alsabbagh; Nasimul Ahsan
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

10.  Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells.

Authors:  Yun Hou; Hua-Qing Wang; Yi Ba
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-18       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.